ClinicalTrials.gg
CompletedNCT05291585Updated Oct 17, 2024

The Dedicated Venous Sinus Thrombectomy Stent for Endovascular Treatment of Cerebral Venous Sinus Thrombosis.

An interventional study of the dedicated venous sinus thrombectomy stent and balloon catheter thrombectomy in Cerebral Venous Sinus Thrombosis, sponsored by Ji Xunming,MD,PhD. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-10-17.

Sponsored by Ji Xunming,MD,PhD · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

A prospective, single-center, open-label,randomized, controlled,non-inferiority clinical trial will be conducted to evaluate the safety and efficacy of a dedicated venous sinus thrombectomy stent for endovascular treatment of cerebral venous sinus thrombosis.

Read the detailed description

Endovascular mechanical thrombectomy is reserved for the treatment of refractory cerebral venous sinus thrombosis (CVST) in the scenario of clinical deterioration in spite of appropriate anticoagulant therapy. However, due to the vascular anatomic and pathophysiological differences, the present used devices,such as stent retriever for arterial occlusion ,aspiration system and balloon catheter cannot provide optimal restoration of venous outflow for high load venous sinus thrombosis.This is a prospective, single-center, open-label, randomized, controlled , non-inferiority clinical trial to evaluate the safety and efficacy of the dedicated venous sinus thrombectomy stent ,which is a novel NiTi- braided Stent Retriever compared to balloon catheter used before in our center. Patients are eligible if they have a radiologically proven CVST, a high probability of poor outcome.

The trial aims to randomize 60 patients with a 1:1 allocation to receive the dedicated venous sinus thrombectomy stent or balloon catheter.

The primary outcome is the success rate of immediate recanalization.The most important secondary outcomes are mRS and mortality rate at 90 days. The intracranial hemorrhage and other adverse events after post-operative 24 hours and 7 days are the principal safety outcomes.

02

Conditions studied

  • Cerebral Venous Sinus Thrombosis

Keywords

  • cerebral venous sinus thrombosis
  • endovascular treatment
  • thrombectomy
03

In context

Lead sponsor

Ji Xunming,MD,PhD is the lead sponsor of 14 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Cerebral venous sinus thrombosis (from onset to randomization less than 28 days) confirmed by cerebral angiography, magnetic resonance venography or computed tomographic venography
  2. Severe form of CVT with a high chance of incomplete recovery, as defined by the presence of one or more of the following risk factors

    1. Clinical deterioration or progression despite anticoagulation
    2. Stupor, Coma (Glasgow coma scale \< 9) or mental status disorder
    3. Involvement of multiple sinus veins results in severe high cranial pressure and rapid vision loss
    4. Venous infarction or intracranial hemorrhage with high load venous sinus thrombosis
    5. Thrombosis of the straight sinus
  3. The subject (or his/her guardian) agrees to participate in this study and signs the

Exclusion criteria

Exclusion Criteria:

Age less than 18 years Duration from onset to randomization more than 28 days Recurrent CVST Pregnancy (women in the puerperium may be included) Isolated cavernous sinus thrombosis or isolated cortical vein thrombosis Clinical and radiological signs of impending transtentorial herniation due to large space-occupying lesions and 4th ventricle compression and hydrocephalus, which requires emergency surgery Recent (\< 2 weeks) major surgical procedure (does not include lumbar puncture) or severe cranial trauma for anti-coagulant or thrombolytic treatment

  1. documented generalized bleeding disorder
  2. concurrent thrombocytopenia (\<100 x 10E9/L)
  3. severe hepatic or renal dysfunction, that interferes with normal coagulation
  4. gastrointestinal tract hemorrhage (\< 3 months, not including hemorrhage from rectal hemorrhoids) Any known serious condition (such as terminal cancer) with a poor short term (1 year) prognosis independent Known allergy against contrast used during endovascular procedures or the thrombolytic or anticoagulation drug used Previously legally incompetent prior to CVST No Other conditions judged by the researcher to be unsuitable for inclusion.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    the dedicated venous sinus thrombectomy stent

    Patients diagnosed with acute or subacute venous sinus thrombosis within 28days from the onset of symptoms to endovascular treatment, regardless of whether anticoagulation has been performed. The dedicated venous sinus thrombectomy stent can be used to remove the thrombus to restore sinus blood flow.

    Device: the dedicated venous sinus thrombectomy stent

  • Active comparator
    balloon catheter thrombectomy

    Intracranial thrombectomy was balloon catheter in conjunction with aspiration performed with a control product

    Device: balloon catheter thrombectomy

Interventions

  • Devicethe dedicated venous sinus thrombectomy stent

    the dedicated venous sinus thrombectomy stent in conjunction with aspiration for CVST patients within 28 days of symptom onset.

  • Deviceballoon catheter thrombectomy

    Intracranial thrombectomy was conducted by using a balloon catheter in conjunction with aspiration as control group.

06

What researchers measure

Primary outcomes

  1. Success rate of immediate recanalization

    3-grade classification scheme that considers different grades for patients with complete recanalization, partial recanalization and no recanalization. Complete recanalization defined as blood flow without any interruption, Partial recanalization defined as small interruptions of continuous blood flow and narrowing of the venous lumen No recanalization defined as interrupted blood flow.

    Time frame: immediately intra-operative

Secondary outcomes

  1. The proportion of functional independence (modified Rankin score 0-2)

    0-No symptoms; 1-No significant disability; 2-Slight disability; 3-Moderate disability; 4-Moderately severe disability; 5-Severe disability; 6-Dead.

    Time frame: up to 7 days and 90 days post-procedure

  2. The time of thrombectomy procedure

    The time of thrombectomy procedure refers to the time from entry of thrombectomy device to vascular recanalization) or the end time of surgery for patients with no vascular recanalization

    Time frame: intra-operative

  3. Changes in NIHSS score

    Changes in NIHSS score 7days or at discharge and 90 days post-procedure compared with pre-procedure.

    Time frame: pre-procedure, up to 7 days and 90 days post-procedure

  4. Success rate of instrument operation

    Device operation success = the number of devices completed conveying to the occlusive segment of the sinus, releasing and retracting in the group/the number of all test devices used in the group ×100%

    Time frame: intra-operative

  5. The proportion of symptom-free and improved

    The symptoms include headache, visual dysfunction, tinnitus, cognitive disorder and epilepsy, etc.

    Time frame: up to 7 days and 90 days post-procedure

  6. CSF opening pressure

    Change of CSF opening pressure 7 days or at discharge post-procedure compared with pre-procedure by lumbar puncture

    Time frame: up to 7days

  7. Modified Rankin Scale

    Distribution of Modified Rankin Scale

    Time frame: up to 7 days and 90 days post-procedure

  8. The incidence of symptomatic intracranial hemorrhage

    Symptomatic intracranial hemorrhage within 7 days post-procedure, specifically intracranial hemorrhage (intracranial parenchymal hematoma, subarachnoid hemorrhage, an ventricular hemorrhage) accompanied by neurological deterioration (NIHSS score increased by ≥4 points compared with pre-procedure.

    Time frame: within 7 days post-procedure

  9. Peri-procedural complications

    Procedure associated complications: vasospasm, dissection, perforation and emboli to new territory.

    Time frame: intra-operative and 7 days post-procedure

  10. All cause mortality

    All cause mortality within 90 days post-procedure

    Time frame: within 90 days post-procedure

  11. Incidence of device defects

    Defects of research devices during clinical trials, such as operational difficulties, broken devices and any incident related with device defects.

    Time frame: intra-operative

  12. Incidence of SAE (serious adverse events) or AE (adverse events)

    Incidence of SAE (serious adverse events) or AE (adverse events) intra-operative, 24 hours, 7 days and 90 days post-procedure

    Time frame: intra-operative, 24 hours, 7 days and 90 days post-procedure

  13. The recurrence rate of CVST

    The recurrence rate of CVST confirmed by clinical manifestations and imaging examinations

    Time frame: up to 7 days and 90 days post-procedure

Other outcomes

  1. CVST pathological markers

    CVST pathological markers of blood, clot and cerebral spinal fluid(CRP,IL-6,NSE,NLR,etc.

    Time frame: pre-procedure, intra-operative, up to 7 days

  2. Imaging database

    neuroimaging: MRV/CTV

    Time frame: pre-procedure and 90 days post-procedure

07

Study locations

1 site
  • Xuan Wu Hospital,Capital Medical University
    Beijing, Beijing 100053, China
08

References and documents

Publications

  • Ferro JM, Canhao P, Stam J, Bousser MG, Barinagarrementeria F; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004 Mar;35(3):664-70. doi: 10.1161/01.STR.0000117571.76197.26. Epub 2004 Feb 19. PubMed 14976332 ↗
  • Lee SK, Mokin M, Hetts SW, Fifi JT, Bousser MG, Fraser JF; Society of NeuroInterventional Surgery. Current endovascular strategies for cerebral venous thrombosis: report of the SNIS Standards and Guidelines Committee. J Neurointerv Surg. 2018 Aug;10(8):803-810. doi: 10.1136/neurintsurg-2018-013973. Epub 2018 Jun 5. No abstract available. PubMed 29871990 ↗
  • Coutinho JM, Zuurbier SM, Bousser MG, Ji X, Canhao P, Roos YB, Crassard I, Nunes AP, Uyttenboogaart M, Chen J, Emmer BJ, Roosendaal SD, Houdart E, Reekers JA, van den Berg R, de Haan RJ, Majoie CB, Ferro JM, Stam J; TO-ACT investigators. Effect of Endovascular Treatment With Medical Management vs Standard Care on Severe Cerebral Venous Thrombosis: The TO-ACT Randomized Clinical Trial. JAMA Neurol. 2020 Aug 1;77(8):966-973. doi: 10.1001/jamaneurol.2020.1022. PubMed 32421159 ↗
  • Fan Y, Yu J, Chen H, Zhang J, Duan J, Mo D, Zhu W, Wang B, Ouyang F, Chen Y, Lan L, Zeng J; Chinese Stroke Association Stroke Council CVST Guideline Writing Committee. Chinese Stroke Association guidelines for clinical management of cerebrovascular disorders: executive summary and 2019 update of clinical management of cerebral venous sinus thrombosis. Stroke Vasc Neurol. 2020 Jun;5(2):152-158. doi: 10.1136/svn-2020-000358. Epub 2020 May 13. PubMed 32409571 ↗
  • Goyal M, Fladt J, Coutinho JM, McDonough R, Ospel J. Endovascular treatment for cerebral venous thrombosis: current status, challenges, and opportunities. J Neurointerv Surg. 2022 Aug;14(8):788-793. doi: 10.1136/neurintsurg-2021-018101. Epub 2022 Jan 12. PubMed 35022302 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2022 to primary completion in Mar 2023, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 2, 2022
First posted
Mar 22, 2022
StartActual
Mar 30, 2022
Primary completionActual
Mar 26, 2023
CompletionActual
Jul 30, 2023
Last update
Oct 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05291585
Lead sponsor
Ji Xunming,MD,PhD
Responsible party
Ji Xunming,MD,PhD (Professor, Capital Medical University) — Sponsor-investigator
First posted
Mar 22, 2022
Start date
Mar 30, 2022
Primary completion
Mar 26, 2023
Completion
Jul 30, 2023
Last update
Oct 17, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion